Syros Pharmaceuticals, Inc. (SYRS)
- Previous Close
5.14 - Open
5.20 - Bid 5.04 x 100
- Ask 5.09 x 100
- Day's Range
5.00 - 5.20 - 52 Week Range
2.09 - 8.17 - Volume
89,493 - Avg. Volume
212,504 - Market Cap (intraday)
135.512M - Beta (5Y Monthly) 1.78
- PE Ratio (TTM)
-- - EPS (TTM)
-5.81 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.25
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
www.syros.comRecent News: SYRS
Performance Overview: SYRS
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SYRS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SYRS
Valuation Measures
Market Cap
135.51M
Enterprise Value
58.06M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
14.45
Price/Book (mrq)
8.13
Enterprise Value/Revenue
5.84
Enterprise Value/EBITDA
-0.37
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.32%
Return on Equity (ttm)
-227.95%
Revenue (ttm)
9.94M
Net Income Avi to Common (ttm)
-164.57M
Diluted EPS (ttm)
-5.81
Balance Sheet and Cash Flow
Total Cash (mrq)
139.53M
Total Debt/Equity (mrq)
372.55%
Levered Free Cash Flow (ttm)
-66.66M